Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis.

Trial Profile

REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TTI 101 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Acronyms REVERT-IPF
  • Sponsors Tvardi Therapeutics

Most Recent Events

  • 27 May 2025 According to a Tvardi Therapeutics media release, the company has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis (IPF).Topline data from the REVERT IPF trial anticipated in 4Q 2025.
  • 27 May 2025 Status changed from recruiting to active, no longer recruiting, according to a Tvardi Therapeutics media release.
  • 22 May 2025 Planned End Date changed from 17 Jul 2025 to 25 Aug 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top